Ischemic Heart DiseaseIMPACT-FFRNCT03030495
Registry of Comprehensive Imaging and Physiological Evaluation of Deferred Lesions Based on FFR
An observational study of Ischemic Heart Disease, run by Samsung Medical Center at 4 sites in South Korea.
Trial summary
1. To compare the risk of atherosclerotic lesion progression and subsequent patient-oriented composite outcomes (all-cause mortality, any MI, or any Ischemia-driven repeat revascularization) between deferred lesions with or without over microvascular disease, defined as physiological classification 2. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Heart Disease
- What is being tested?
- Comprehensive physiologic evaluation and Intravascular imaging devices
- Type of treatment
- Medical device
- How many people
- 1,400 participants
- Where
- 4 sitesSouth Korea
- Study dates
- 1 Dec 2016to 31 Dec 2025
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size ≥2.5 mm.
Who may be able to join
- Subject must be ≥ 18 years
- Patients suspected with ischemic heart disease
- Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size≥2.5 mm
- Patients whose coronary stenosis were evaluated by invasive imaging techniques (intravascular ultrasound and optical coherence tomography) and physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written informed consent to any study related procedure
Who cannot join
- End-staged renal disease on peritoneal dialysis or hemodialysis (estimated GFR < 15mL/min)
- Acute hepatic injury
- Cardiogenic shock (systolic blood pressure < 90mmHg or requiring inotropics to maintain blood pressure > 90mmHg)
- The patient has a known hypersensitivity or contraindication to any of the following medications: statin, ezetimibe, heparin, aspirin, clopidogrel, prasugrel, ticagrelor
- Non-cardiac co-morbid conditions are present with life expectancy <2 year (per site investigator's medical judgment)
- Unable to perform invasive imaging study (intravascular ultrasound and optical coherence tomography) or physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)
Trial locations and contacts
4 sites in 1 country.
South Korea4 sites
Keimyung University Dongsan Medical Center
Daegu
Inje University Ilsan Paik Hospital
Goyang-si
Samsung Medical Center
Seoul
Seoul National University Hospital
Seoul
About this study
Official title: IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions With Contemporary Medical Treatment Based on Fractional Flow Reserve-guided Strategy
- To compare the risk of atherosclerotic lesion progression and subsequent patient-oriented composite outcomes (all-cause mortality, any MI, or any Ischemia-driven repeat revascularization) between deferred lesions with or without over microvascular disease, defined as physiological classification
- To explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment
Read the detailed description
The coronary artery system has 3 components with different functions: conductive epicardial coronary arteries, arterioles, and capillaries. When any one of these systems fails, myocardial ischemia can occur. Therefore, the presence of epicardial coronary artery stenosis is not necessarily a prerequisite for ischemic heart disease (IHD). Although it has not been established that microvascular disease is independent of macrovascular disease, clinical studies have consistently shown that the presence of microvascular disease is an independent predictor of poor clinical outcomes, especially in patients with acute myocardial infarction (MI).
The pressure-derived fractional flow reserve (FFR) index has become a standard invasive method to evaluate the functional significance of epicardial coronary artery stenosis, and clinical outcomes of FFR-guided percutaneous coronary intervention (PCI) have proven to be better than those of angiography-guided PCI or medical treatment. Although FFR-guided PCI has been reported to improve patient outcomes and FFR is now regarded as the gold-standard invasive method to assess the functional significance of coronary artery stenosis, there is still room for further improvement in the diagnosis and treatment of patients with high FFR. In the FAME II study, 14.6% of the registry arm (FFR > 0.80 and deferral of PCI) experienced persistent angina, and 9.0% of these patients had clinical events during a 2-year follow-up period.
Therefore, microvascular assessment using coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR) can provide additional diagnostic and prognostic insights for IHD patients, especially in those with high FFR.
Recently, Lee et al. (JACC 2016) investigated clinical outcomes among patients with high-FFR and deferred revascularization, according to physiologic classification using CFR and IMR. Lee et al. firstly presented that 7.0% of patients with high FFR had high IMR and low CFR and were regarded as having overt microvascular disease. Although the proportion of patients with high FFR who had overt microvascular disease was small, Group D had the poorest clinical outcomes during follow-up. The presence of overt microvascular disease was an independent prognostic factor in patients with high FFR. In addition, the presence of overt microvascular disease had additive prognostic value aside from clinical risk factors, with significantly improved discriminant function of the prediction model. These results suggest that the invasive physiologic assessment for microvascular disease combined with CFR and IMR can help identify patients at high risk for future cardiovascular events among those with high FFR.
Previous studies have shown that the presence of microvascular disease is associated with a higher risk of cardiovascular events such as cardiac death, MI, or revascularization in patients without flow-limiting epicardial stenosis. Several mechanisms have been proposed for the association of microvascular disease and poor clinical outcomes. In addition to myocardial ischemia, microvascular disease is reported to be associated with endothelial dysfunction and inflammatory activity that precedes intimal thickening, lipid deposition in the macrovascular system, and coronary vasomotor dysfunction. In a study by Dhawan et al., coronary microvascular dysfunction in patients with non-obstructive coronary artery disease was associated with higher serum high-sensitivity C-reactive protein and a higher frequency of thin-cap fibroatheroma.
In the Lee et al.'s study, the higher clinical event rates in patients with overt microvascular disease resulted from cardiac death and revascularization rates higher than those of the other groups. These results imply that the presence of overt microvascular disease can induce accentuated atherosclerotic progression and subsequent clinical events including cardiac death and ischemia-driven repeat revascularization.
Therefore, the IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions with Contemporary Medical Treatment based on Fractional Flow Reserve-guided Strategy (IMPACT-FFR registry) was designed to compare the risk of atherosclerotic plaque progression and subsequent clinical events between deferred lesions with or without over microvascular disease, defined as physiological classification and also to explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment.
- Conditions
- Ischemic Heart Disease
- Being tested
- Comprehensive physiologic evaluation, Intravascular imaging devices
- Keywords
- Ischemic Heart Disease, Stable angina, Fractional flow reserve, Index of Microcirculatory Resistance, Coronary Flow Reserve, Intravascular Imaging
- Medical subject headings
- Myocardial Ischemia, Angina, Stable
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Comprehensive physiologic evaluationDevice
Also called Comprehensive physiologic evaluation using pressure-temperature sensor wire
Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
Intravascular imaging devicesDevice
Also called Intravascular ultrasound or optical coherence tomography
Intravascular ultrasound or optical coherence tomography
| Study group | Role | What they receive |
|---|---|---|
| Overt microvascular disease | Fractional flow reserve>0.80, coronary flow reserve<2 \& Index of microvascular resistance>25U Receives: Device: Comprehensive physiologic evaluation; Device: Intravascular imaging devices | |
| No Overt microvascular disease | Fractional flow reserve>0.80, coronary flow reserve>2 \& Index of microvascular resistance<25U Receives: Device: Comprehensive physiologic evaluation; Device: Intravascular imaging devices |
What is being measured
The primary outcome is the main question the study is designed to answer.
patient-oriented composite outcome
a composite of all-cause death, MI, any repeat revascularization
Measured: 24 months
Secondary outcomes (15)
patient-oriented composite outcome
a composite of all-cause death, MI, any repeat revascularization
Measured: 12 months
patient-oriented composite outcome
a composite of all-cause death, MI, any repeat revascularization
Measured: 60 months
All-cause death
All-cause death
Measured: 24 months
cardiac death
cardiac death
Measured: 24 months
Target-vessel nonfatal MI
Target-vessel nonfatal MI
Measured: 24 months
Non-target vessel nonfatal MI
Non-target vessel nonfatal MI
Measured: 24 months
All-cause nonfatal MI
All-cause nonfatal MI
Measured: 24 months
Seattle Angina Questionnaires
Angina severity measured with Seattle Angina Questionnaires
Measured: 24 months
Change in normalized total atheroma volume
TAVnormalized = [Σ (EEM CSA - lumen CSA) / no. of images in pullback images in cohort] X median no. of images in cohort
Measured: 12 months
Change in total atheroma volume index
Indexed total atheroma volume (TAVi): Σ(EEM CSA -lumen CSA)/plaque length
Measured: 12 months
Change in fibrous cap thickness by OCT
Change in fibrous cap thickness by OCT at 12-month
Measured: 12 months
Change in Plaque burden at minimum lumen area site
Change in Plaque burden at minimum lumen area site at 12-month Plaque burden = (EEM-MLA)/EEM x 100
Measured: 12 months
Change in Fractional flow reserve
Change in Fractional flow reserve at 12-month
Measured: 12 months
Change in coronary flow reserve
Change in coronary flow reserve at 12-month
Measured: 12 months
Change in index of microcirculatory resistance
Change in index of microcirculatory resistance at 12-month
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2017 (estimated)
- Study start1 Dec 2016
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ischemic Heart DiseaseStudies of the same condition, open and under way.
- More trials run by Samsung Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,400 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Samsung Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Seoul National University Hospital, Inje University Ilsan Paik Hospital, Ulsan University Hospital, Keimyung University Dongsan Medical Center
- Responsible party
- Principal investigator, Joo-Yong Hahn, Samsung Medical Center
- Investigators
- Joo-Yong Hahn, MD, PhD, Study chair, Samsung Medical CenterBon-Kwon Koo, MD, PhD, Study chair, Seoul National University HospitalJoo-Yong Hahn, MD, PhD, Principal investigator, Samsung Medical CenterJoo Myung Lee, MD, MPH, PhD, Principal investigator, Samsung Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03030495
- Sponsor's protocol ID
- IMPACT16453143
- Acronym
- IMPACT-FFR
- Status last verified
- May 2025
- First submitted
- 20 Dec 2016
- Last updated
- 15 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions With Contemporary Medical Treatment Based on Fractional Flow Reserve-guided Strategy
- ClinicalTrials.gov ID
- NCT03030495
- Acronym / sponsor ID
- IMPACT-FFR / IMPACT16453143
- Conditions
- Ischemic Heart Disease
- Keywords
- Ischemic Heart Disease, Stable angina, Fractional flow reserve, Index of Microcirculatory Resistance, Coronary Flow Reserve, Intravascular Imaging
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,400 participants (estimated)
- Lead sponsor
- Samsung Medical CenterUniversity, hospital or other
- Collaborators
- Seoul National University Hospital, Inje University Ilsan Paik Hospital, Ulsan University Hospital, Keimyung University Dongsan Medical Center
- Study start
- 1 Dec 2016 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 25 Jan 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To compare the risk of atherosclerotic lesion progression and subsequent patient-oriented composite outcomes (all-cause mortality, any MI, or any Ischemia-driven repeat revascularization) between deferred lesions with or without over microvascular disease, defined as physiological classification
- To explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment
Detailed description
The coronary artery system has 3 components with different functions: conductive epicardial coronary arteries, arterioles, and capillaries. When any one of these systems fails, myocardial ischemia can occur. Therefore, the presence of epicardial coronary artery stenosis is not necessarily a prerequisite for ischemic heart disease (IHD). Although it has not been established that microvascular disease is independent of macrovascular disease, clinical studies have consistently shown that the presence of microvascular disease is an independent predictor of poor clinical outcomes, especially in patients with acute myocardial infarction (MI).
The pressure-derived fractional flow reserve (FFR) index has become a standard invasive method to evaluate the functional significance of epicardial coronary artery stenosis, and clinical outcomes of FFR-guided percutaneous coronary intervention (PCI) have proven to be better than those of angiography-guided PCI or medical treatment. Although FFR-guided PCI has been reported to improve patient outcomes and FFR is now regarded as the gold-standard invasive method to assess the functional significance of coronary artery stenosis, there is still room for further improvement in the diagnosis and treatment of patients with high FFR. In the FAME II study, 14.6% of the registry arm (FFR > 0.80 and deferral of PCI) experienced persistent angina, and 9.0% of these patients had clinical events during a 2-year follow-up period.
Therefore, microvascular assessment using coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR) can provide additional diagnostic and prognostic insights for IHD patients, especially in those with high FFR.
Recently, Lee et al. (JACC 2016) investigated clinical outcomes among patients with high-FFR and deferred revascularization, according to physiologic classification using CFR and IMR. Lee et al. firstly presented that 7.0% of patients with high FFR had high IMR and low CFR and were regarded as having overt microvascular disease. Although the proportion of patients with high FFR who had overt microvascular disease was small, Group D had the poorest clinical outcomes during follow-up. The presence of overt microvascular disease was an independent prognostic factor in patients with high FFR. In addition, the presence of overt microvascular disease had additive prognostic value aside from clinical risk factors, with significantly improved discriminant function of the prediction model. These results suggest that the invasive physiologic assessment for microvascular disease combined with CFR and IMR can help identify patients at high risk for future cardiovascular events among those with high FFR.
Previous studies have shown that the presence of microvascular disease is associated with a higher risk of cardiovascular events such as cardiac death, MI, or revascularization in patients without flow-limiting epicardial stenosis. Several mechanisms have been proposed for the association of microvascular disease and poor clinical outcomes. In addition to myocardial ischemia, microvascular disease is reported to be associated with endothelial dysfunction and inflammatory activity that precedes intimal thickening, lipid deposition in the macrovascular system, and coronary vasomotor dysfunction. In a study by Dhawan et al., coronary microvascular dysfunction in patients with non-obstructive coronary artery disease was associated with higher serum high-sensitivity C-reactive protein and a higher frequency of thin-cap fibroatheroma.
In the Lee et al.'s study, the higher clinical event rates in patients with overt microvascular disease resulted from cardiac death and revascularization rates higher than those of the other groups. These results imply that the presence of overt microvascular disease can induce accentuated atherosclerotic progression and subsequent clinical events including cardiac death and ischemia-driven repeat revascularization.
Therefore, the IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions with Contemporary Medical Treatment based on Fractional Flow Reserve-guided Strategy (IMPACT-FFR registry) was designed to compare the risk of atherosclerotic plaque progression and subsequent clinical events between deferred lesions with or without over microvascular disease, defined as physiological classification and also to explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Overt microvascular disease | – | Device: Comprehensive physiologic evaluation, Device: Intravascular imaging devicesFractional flow reserve>0.80, coronary flow reserve<2 \& Index of microvascular resistance>25U |
| No Overt microvascular disease | – | Device: Comprehensive physiologic evaluation, Device: Intravascular imaging devicesFractional flow reserve>0.80, coronary flow reserve>2 \& Index of microvascular resistance<25U |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size ≥2.5 mm.
Key inclusion criteria (5 listed)
- Subject must be ≥ 18 years
- Patients suspected with ischemic heart disease
- Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size≥2.5 mm
- Patients whose coronary stenosis were evaluated by invasive imaging techniques (intravascular ultrasound and optical coherence tomography) and physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written informed consent to any study related procedure
Key exclusion criteria (6 listed)
- End-staged renal disease on peritoneal dialysis or hemodialysis (estimated GFR < 15mL/min)
- Acute hepatic injury
- Cardiogenic shock (systolic blood pressure < 90mmHg or requiring inotropics to maintain blood pressure > 90mmHg)
- The patient has a known hypersensitivity or contraindication to any of the following medications: statin, ezetimibe, heparin, aspirin, clopidogrel, prasugrel, ticagrelor
- Non-cardiac co-morbid conditions are present with life expectancy <2 year (per site investigator's medical judgment)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Comprehensive physiologic evaluationAlso: Comprehensive physiologic evaluation using pressure-temperature sensor wireComprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance | Device | No Overt microvascular disease, Overt microvascular disease |
| Intravascular imaging devicesAlso: Intravascular ultrasound or optical coherence tomographyIntravascular ultrasound or optical coherence tomography | Device | No Overt microvascular disease, Overt microvascular disease |
Primary outcome
patient-oriented composite outcome
Time frame: 24 months
a composite of all-cause death, MI, any repeat revascularization
15 secondary outcomes
patient-oriented composite outcome
Time frame: 12 months
patient-oriented composite outcome
Time frame: 60 months
All-cause death
Time frame: 24 months
cardiac death
Time frame: 24 months
Target-vessel nonfatal MI
Time frame: 24 months
Non-target vessel nonfatal MI
Time frame: 24 months
All-cause nonfatal MI
Time frame: 24 months
Seattle Angina Questionnaires
Time frame: 24 months
Change in normalized total atheroma volume
Time frame: 12 months
Change in total atheroma volume index
Time frame: 12 months
Change in fibrous cap thickness by OCT
Time frame: 12 months
Change in Plaque burden at minimum lumen area site
Time frame: 12 months
Change in Fractional flow reserve
Time frame: 12 months
Change in coronary flow reserve
Time frame: 12 months
Change in index of microcirculatory resistance
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2025.
- Individual participant dataSharing planned: Yes. After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
Related trials for Ischemic Heart Disease
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joo-Yong Hahn, MD, PhD study chair
Samsung Medical Center
Bon-Kwon Koo, MD, PhD study chair
Seoul National University Hospital
Joo-Yong Hahn, MD, PhD principal investigator
Samsung Medical Center
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ischemic Heart Disease, run by Samsung Medical Center at 4 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
patient-oriented composite outcome (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.